Memorial Sloan Kettering Cancer Center
sPARK.
Screening · Pathology AI · Antigen · Repair · KRAS
A translational pancreatic cancer research laboratory developing precision therapeutics — from bench to bedside — in Manhattan, New York.
22026 Publications
NEJM+ Nature Medicine
5Research Pillars
What We Do
Research Programs
Five interconnected sPARK pillars driving translational breakthroughs in pancreatic ductal adenocarcinoma (PDAC) — now expanding across gastrointestinal cancers through the GRIT initiative.
High-throughput Screening
Genetic and small-molecule screens — including CRISPR-based functional genomics — to find combination strategies, resistance mechanisms, and novel targets in PDAC.
Pathology AI
AI-enabled pathology and multimodal data integration to connect tissue phenotypes with therapeutic vulnerabilities in PDAC.
Neoantigens & Biologics
Pipelines for neoantigen discovery and biologic modalities targeting tumor-specific epitopes.
DNA Damage Repair & PARP-Immunotherapy
Combining DNA-damage-repair targeting with immunotherapy in BRCA/PALB2-mutated and HRD pancreatic cancer.
Nature Medicine 2026
KRAS-driven Vulnerabilities
Targeting KRAS G12D — the most common variant in PDAC — with first-in-class degraders and RAS(ON) inhibitors.
NEJM 2026
GRIT — GI RAS Innovative Therapeutics
A cross-tumor initiative extending RAS-directed precision therapy across gastrointestinal cancers — from pancreatic cancer to biliary tract, gastric/GEJ, appendiceal, and colorectal cancer.
Initiative
Biliary Tract Cancer
Extending our KRAS/RAS and precision-oncology work into biliary tract cancer — genomic determinants of chemotherapy benefit today, and RAS-directed trials next.
New · 2026
Latest Work
Recent Publications
Selected recent publications across KRAS-directed therapy, DDR/immunotherapy, neoantigen vaccines, and translational data science.
2026Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic CancerN Engl J Med2026Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic CancerN Engl J Med2026Pembrolizumab and Olaparib in HRD Metastatic Pancreatic Cancer: The POLAR TrialNature Medicine2025Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survivalNature Medicine 31(2), 466–4772025RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancerNature 639(8056), 1042–10512024Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancerCancer Cell 42(9), 1614–1629
Collaboration
Co-authorship Network
A curated map of the research community, highlighting frequent collaborators and the strength of co-authorship ties across clinical, research, and data science groups.
PIClinicalResearchData / AI
Meetings
Recent Congress Presentations
Presentation lists for GI ESMO, AACR Pancreas, AACR, and related meetings can be added here as details are finalized.
Trials & Programs
Projects
Named clinical trials and translational efforts advancing precision therapeutics in pancreatic cancer.
Published
POLAR Trial
Maintenance pembrolizumab + olaparib in HRD metastatic pancreatic cancer
Investigator-initiated phase 2 trial of maintenance pembrolizumab + olaparib in biomarker-stratified metastatic pancreatic cancer.
Active
Setidegrasib (ASP3082)
First-in-human KRAS G12D targeted protein degrader
First-in-human phase 1 trial of setidegrasib, a first-in-class KRAS G12D targeted protein degrader, in advanced PDAC and NSCLC.
Active
Daraxonrasib (RMC-6236)
Oral RAS(ON) multiselective inhibitor
Phase 1–2 study of daraxonrasib, an oral RAS(ON) multiselective inhibitor, in previously treated RAS-mutated pancreatic cancer; phase 3 RASolute 302 reported in 2026.
Active
RNA Neoantigen Vaccine
Personalized mRNA vaccines targeting tumor neoantigens
Personalized RNA neoantigen vaccine program priming durable, long-lived T-cell responses in pancreatic cancer.